Is Tradjenta a subsidiary of Boehringer Ingelheim?

Tradjenta is not a subsidiary; it is a product line owned by Boehringer Ingelheim. The linagliptin molecule was developed internally and the brand is marketed globally under Boehringer's ownership, with Eli Lilly co-marketing in the United States and other markets.

Is Tradjenta publicly traded?

No. Tradjenta's owner, Boehringer Ingelheim, is a private, family-owned company with no stock listing. Investors cannot buy shares in either the brand or its parent.

When was Tradjenta approved?

The FDA approved Tradjenta (linagliptin) on May 2, 2011, for type 2 diabetes in adults. European approval followed in 2011 under the Trajenta name, and fixed-dose combinations arrived in subsequent years.

Who developed Tradjenta?

Linagliptin was developed by Boehringer Ingelheim's internal research organization. It is co-marketed under the Boehringer-Lilly diabetes alliance launched in 2011, which also covers Jardiance.

What is Tradjenta's market position?

Tradjenta is a mid-tier DPP-4 inhibitor whose niche is renal-safe dosing, distinguishing it from sitagliptin. The class overall is declining as SGLT2 inhibitors and GLP-1 agonists take share, and generic linagliptin now competes in many markets.

Are there generic versions of Tradjenta?

Yes. Generic linagliptin gained FDA approvals starting in 2021, with additional manufacturers including Teva approved through 2026. Availability varies by market depending on remaining patent protections and launch timing.

Healthcare & Pharmaceuticals

Who Owns Tradjenta?

Tradjenta is owned by Boehringer Ingelheim, a family-owned German pharmaceutical company headquartered in Ingelheim am Rhein. The brand name for linagliptin, Tradjenta was approved by the FDA on May 2, 2011, and is co-marketed in the United States through a diabetes alliance with Eli Lilly and Company. Boehringer Ingelheim reported 2025 net sales of EUR 27.75 billion across human pharmaceuticals and animal health.

Twitter Facebook LinkedIn

Parent Company

Boehringer Ingelheim

Founded

2011

Status

Private

Headquarters

Ingelheim am Rhein, Rhineland-Palatinate, Germany

Tradjenta Timeline

1885

Boehringer Ingelheim

Parent company established in Ingelheim am Rhein, Rhineland-Palatinate, Germany

Company Founded

2011

Tradjenta

Founded by Boehringer Ingelheim (internal development)

Founded

GlobalOfficial Website

Who Owns Tradjenta?

Parent Company: Boehringer Ingelheim
Ownership Type: Product line
Company Type: Privately Held

Brand	Parent Company	Ownership Type
Tradjenta	Boehringer Ingelheim	Product line

Where to Buy

Disclosure: We may earn commission from purchases

Tradjenta on Amazon

History of Tradjenta

Founded: 2011
Founders: Boehringer Ingelheim (internal development)

Linagliptin was developed by Boehringer Ingelheim's research organization as a once-daily DPP-4 inhibitor for type 2 diabetes. Its distinguishing pharmacology is primary elimination through bile and the gut rather than the kidneys, which means no dose adjustment is required for patients with renal impairment, a clinically meaningful differentiator from sitagliptin-based rivals.

The FDA approved Tradjenta on May 2, 2011, and European approval followed the same year under the name Trajenta in many markets. Launch coincided with the start of the Boehringer-Lilly diabetes alliance, which co-promoted the product in the United States and positioned it as the renal-friendly DPP-4 option.

Fixed-dose combinations expanded the franchise: Jentadueto combined linagliptin with metformin, and Glyxambi combined it with empagliflozin, the SGLT2 inhibitor that later became the alliance's flagship product. As Jardiance's growth eclipsed the DPP-4 class, Tradjenta settled into a steady mid-life brand role.

Patent protection began eroding in the 2020s. The compound patent expired in major markets between 2023 and 2025, and generic linagliptin gained FDA approvals from 2021 onward, with additional approvals including Teva in May 2026. In South Korea, generics launched in mid-2024 despite Boehringer's legal warnings that secondary patents remained in force. By late 2026, Tradjenta faces generic competition in many markets while remaining a prescribed option in the DPP-4 class.

About Boehringer Ingelheim

Is Boehringer Ingelheim family-owned?
Yes. Boehringer Ingelheim has been continuously family-owned since 1885, held by the Boehringer, von Baumbach, and Engelhorn families. It has never listed shares publicly and states it intends to remain independent.

Is Boehringer Ingelheim publicly traded?
No. Boehringer Ingelheim is a private company with no stock listing. It is one of the world's largest privately held pharmaceutical companies and cannot be invested in through public markets.

When was Boehringer Ingelheim founded?
Boehringer Ingelheim was founded in 1885 in Ingelheim am Rhein, Germany, initially producing tartaric acid. It expanded into pharmaceuticals in the late 19th century and has operated for more than 140 years.

Who founded Boehringer Ingelheim?
Albert Boehringer founded the company in 1885. His descendants across the Boehringer, von Baumbach, and Engelhorn families still own it, now in the fifth and sixth generations.

What is Boehringer Ingelheim's market position?
Boehringer Ingelheim is a top-20 global pharmaceutical company with 2025 net sales of EUR 27.75 billion. Its largest product is Jardiance at EUR 8.8 billion, and it is also a top-tier animal health company led by the NexGard franchise.

Who leads Boehringer Ingelheim?
Shashank Deshpande has been chairman of the Board of Managing Directors since mid-2025, succeeding Hubertus von Baumbach, a fifth-generation family member who moved to the shareholders' committee. Deshpande previously led the Human Pharma division.

Founded: 1885
Headquarters: Ingelheim am Rhein, Rhineland-Palatinate, Germany
Company Type: Privately Held
Revenue: EUR 27.75 billion (FY2025)
Employees: Approximately 54,300

Visit Boehringer Ingelheim website

View full company profile for Boehringer Ingelheim

Where Is Tradjenta Made / Based?

Headquarters: Ingelheim am Rhein, Rhineland-Palatinate, Germany
Manufacturing / Operations: Germany, United States

Tradjenta Categories & Tags

Diabetes Type 2 Diabetes Dpp 4 Inhibitor Prescription Endocrinology

Tradjenta Ownership: Pros & Cons

Advantages

+Boehringer's global infrastructure supports broad market access
+Lilly alliance supplies co-promotion scale in the United States
+Renal-safe pharmacology keeps a defined clinical niche within the class
+Combination products extend the molecule's franchise life
+Stable revenue contribution inside a diversified pharma portfolio

Considerations

-Generic competition is expanding as patents expire across markets
-DPP-4 class is losing share to SGLT2 inhibitors and GLP-1 agonists
-Private parent limits visibility into brand-level sales performance
-Patent litigation outcomes vary by jurisdiction
-Clinical differentiation narrows as generics commoditize the molecule

Frequently Asked Questions About Tradjenta

Sources & Further Reading

Competitors to Tradjenta

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
Januvia	Merck	USA	2006	Mass market	Global	All Genders
Nesina	Takeda	Japan	2013	Mass market	Global	All Genders
Onglyza	Astrazeneca	United Kingdom	2009	Mass market	Global	All Genders
Metformin	Bristol Myers Squibb	USA	1994	Mass market	Global	All Genders
Lantus	Sanofi	France	2000	Premium	Global	All-ages